Agenus(AGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AGEN Agenus

Trading 04-29 15:59:26 EDT

3.85

-0.04

-1.16%

High3.87	Low3.64	Vol534.32K
Open3.81	D1 Closing3.89	Amplitude5.91%
Mkt Cap147.64M	Tradable Cap137.04M	Total Shares38.40M
T/O2.00M	T/O Rate1.50%	Tradable Shares35.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AGEN","market":"US","secType":"STK","nameCN":"Agenus","latestPrice":3.845,"timestamp":1777492764045,"preClose":3.89,"halted":0,"volume":534322,"delay":0,"changeRate":-0.011568123393316176,"floatShares":35642200,"shares":38398354,"eps":-0.003396,"marketStatus":"Trading","change":-0.045,"latestTime":"04-29 15:59:26 EDT","open":3.81,"high":3.87,"low":3.64,"amount":2004895.2978059999,"amplitude":0.059126,"askPrice":3.85,"askSize":2751,"bidPrice":3.84,"bidSize":3657,"shortable":3,"etf":0,"ttmEps":-0.003396,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777492800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":949640400000,"exchange":"NASDAQ","adjPreClose":3.89,"preHourTrading":{"tag":"盘前","latestPrice":3.92,"preClose":3.89,"latestTime":"08:59 EDT","volume":763,"amount":2991.5989362,"timestamp":1777467583276,"change":0.03,"changeRate":0.007712,"amplitude":0.023136},"volumeRatio":0.553294,"impliedVol":1.3545,"impliedVolPercentile":0.8845},"requestUrl":"/m/hq/s/AGEN/tweets","defaultTab":"tweets","newsList":[{"id":"2629037453","title":"Agenus to present first Phase 2 botensilimab melanoma data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629037453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629037453?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:00","pubTimestamp":1776780037,"startTime":"0","endTime":"0","summary":"Agenus disclosed four ASCO 2026 abstracts for botensilimab, alone or with balstilimab, spanning melanoma, colorectal cancer, and translational research.First Phase 2 data in advanced cutaneous melanoma refractory or resistant to anti-PD-1 therapy will be presented May 31, 2026.Colorectal cancer updates will be presented May 30, 2026, outlining ongoing late-stage and adjuvant studies for patients with microsatellite-stable disease.Release did not report clinical outcomes, focusing instead on upcoming data readouts that could shape development priorities across melanoma and colorectal cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL7skswF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629036106","title":"Agenus names BAP Pharma exclusive global partner for botensilimab-balstilimab access programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2629036106","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629036106?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:00","pubTimestamp":1776772855,"startTime":"0","endTime":"0","summary":"Agenus named BAP Pharma exclusive global partner to run authorized access programs for botensilimab plus balstilimab.Scope covers France AAC compassionate-use pathway, which is government reimbursed, alongside paid named-patient programs in select countries outside United States.BAP Pharma will manage program requests, case coordination, distribution logistics, payment processing effective immediately.Agenus reported more than 270 physician inquiries from more than 30 countries for access through these pathways.Patients have already been treated via paid named-patient programs in countries including United Kingdom, Switzerland, Greece.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3ZC9MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629797247","title":"Agenus announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2629797247","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629797247?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:23","pubTimestamp":1776720183,"startTime":"0","endTime":"0","summary":"Agenus scheduled annual stockholder meeting as virtual event on June 16, 2026.Ballot includes election of Garo Armen and Jennifer Buell as Class II directors for terms expiring at 2029 annual meeting.Shareholders to vote on raising 2019 Equity Incentive Plan share reserve by 5,000,000 shares.Proposal seeks approval for one-time stock option exchange, with replacement options for directors and executive officers struck at 150% of exchange-date market price.Other items include expanding 2019 Employee Stock Purchase Plan authorization to 200,000 shares, advisory vote on 2025 executive pay, ratification of KPMG as auditor for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to gene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL4MrWFy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628638782","title":"Agenus reports Phase 2 results from BOT and BAL with agenT-797","url":"https://stock-news.laohu8.com/highlight/detail?id=2628638782","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628638782?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:51","pubTimestamp":1776459062,"startTime":"0","endTime":"0","summary":"Agenus (AGEN) announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agenus-reports-phase-2-results-from-bot-and-bal-with-agent-797-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agenus-reports-phase-2-results-from-bot-and-bal-with-agent-797-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGEN","BAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628784758","title":"BRIEF-Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2628784758","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628784758?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:46","pubTimestamp":1776458764,"startTime":"0","endTime":"0","summary":"BRIEF-Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal CancerApril 17 (Reuters) - A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nTUA2JKG77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628378429","title":"Agenus reports Phase II data showing 77% disease control in PD-1 refractory gastroesophageal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2628378429","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628378429?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:43","pubTimestamp":1776458613,"startTime":"0","endTime":"0","summary":"Agenus reported Phase II results from an investigator-initiated study testing botensilimab, balstilimab, agenT-797, ramucirumab, paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma.Study showed high rates of disease control, with a subset of patients showing durable survival beyond 20 months.Induction dosing strategy delivered better outcomes than starting full combination immediately, supporting a sequencing approach that could shape future development plans.Trial missed primary response endpoint, but durability signal supported further study of regimen in this hard-to-treat setting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Busines","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL8l2zyl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628842547","title":"Agenus Inc - Study Does Not Meet Primary Endpoint of Objective Response Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2628842547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628842547?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:43","pubTimestamp":1776458580,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nTUA2JKG77:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624865299","title":"Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2624865299","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624865299?lang=en_us&edition=fundamental","pubTime":"2026-04-03 19:30","pubTimestamp":1775215825,"startTime":"0","endTime":"0","summary":"Agenus flagged new Phase II trial data in PD-1 refractory gastroesophageal cancer for future presentation at AACR 2026.Study evaluates botensilimab with balstilimab alongside MiNK Therapeutics’ allogeneic iNKT cell therapy agenT-797.Update targets checkpoint-inhibitor resistant disease, a setting where treatment options remain limited.Presentation scheduled for April 20, 2026, during AACR Annual Meeting in San Diego.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire  on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL4qCGV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624652967","title":"Agenus Announces Data From Phase Ii Study of BOT+Bal in Combination With Agent-797 in Pd-1 Refractory Gastroesophageal Cancer to Be Presented at Aacr 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624652967?lang=en_us&edition=fundamental","pubTime":"2026-04-03 19:30","pubTimestamp":1775215800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nTUA8Z6FYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624851312","title":"Agenus Says First Patient Enrolled in Phase 3 Colorectal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624851312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624851312?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:09","pubTimestamp":1775045348,"startTime":"0","endTime":"0","summary":"Agenus  said Wednesday that the first patient has been enrolled in its phase 3 trial evaluating the immunotherapy combination of botensilimab plus balstilimab against standard care in patients with a type of colorectal cancer.The company said the trial, led by the Canadian Cancer Trials Group, spans Canada, France, Australia and New Zealand, with more than 100 sites participating.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590068","title":"Agenus enrolls first patient in Phase 3 BATTMAN trial for BOT+BAL in MSS mCRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590068","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590068?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043047,"startTime":"0","endTime":"0","summary":"Agenus enrolled first patient in global Phase 3 BATTMAN  trial testing botensilimab with balstilimab versus best supportive care in refractory, unresectable MSS or pMMR metastatic colorectal cancer.No results have been presented; trial will generate registrational data intended to support potential approval pathway for BOT+BAL in this setting.Study targets population that represents about 95% of metastatic colorectal cancer cases, addressing segment widely viewed as resistant to immunotherapy.BATTMAN plans to enroll about 830 patients across more than 100 sites in Canada, France, Australia, New Zealand.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6b2ZlX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624059022","title":"Agenus Announces First Patient Enrolled in Global Phase 3 Battman Trial of BOT+Bal Immunotherapy Combination in Mss or Pmmr Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2624059022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624059022?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA2Q7XZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594025","title":"Agenus: Strengthening Bot/Bal Clinical Profile and Capital-Efficient Path to Registration Underpin Positive Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594025?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:15","pubTimestamp":1775038556,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Agenus and keeping the price target at $23.00. Emily Bodnar’s rating is based ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/agenus-strengthening-bot-bal-clinical-profile-and-capital-efficient-path-to-registration-underpin-positive-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/agenus-strengthening-bot-bal-clinical-profile-and-capital-efficient-path-to-registration-underpin-positive-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891827","title":"Agenus to host stakeholder webcast on BOT+BAL immunotherapy program; Q&A to follow live session","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891827","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891827?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:57","pubTimestamp":1774558671,"startTime":"0","endTime":"0","summary":"Agenus will host a stakeholder webcast on March 31, 2026, at 4:30 p.m. ET.The webcast will cover updates on botensilimab and balstilimab and patient access programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL1mHD9b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622452857","title":"Agenus securities class action dismissed in full; Massachusetts federal court denies leave to amend","url":"https://stock-news.laohu8.com/highlight/detail?id=2622452857","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622452857?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:25","pubTimestamp":1774527929,"startTime":"0","endTime":"0","summary":"On March 24, 2026, a federal court in Massachusetts issued an order in a putative securities class action against Agenus and several executives.The case is Byron Olsen v. Agenus, et al., Civil Action No. 24-CV-12299-AK.The court granted the defendants’ motion to dismiss the amended complaint in full.The order also denied the plaintiff’s request for leave to amend.Named individual defendants include Garo Armen, Christine Klaskin, Steven O'Day, and Todd Yancey.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL1cSswj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427179","title":"Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427179","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427179?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:22","pubTimestamp":1773955325,"startTime":"0","endTime":"0","summary":"Mink Therapeutics appointed Melissa Orilall as Principal Financial Officer, effective March 13, 2026.Orilall is Vice President, Global Financial Operations at Agenus and previously worked at Whitehead Institute for Biomedical Research and in corporate banking.Austin Charette was appointed Principal Accounting Officer, effective March 13, 2026.Charette is Senior Director, Financial Reporting and Compliance at Agenus and previously worked at Deloitte & Touche.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6NqBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620401833","title":"Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401833","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401833?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:22","pubTimestamp":1773786166,"startTime":"0","endTime":"0","summary":"Agenus (NasdaqCM:AGEN) has swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00, with net income of US$63.9 million for the period. The company has seen quarterly revenue move from US$23.5 million in Q2 2024 to US$26.8 million in Q4 2024 and then to US$30.2 million in Q3 2025, while EPS shifted from a loss of US$2.52 per share in Q2 2024 to a loss of US$2.00 in Q4 2024 and then to a profit of US$2.00 in Q3 2025, indicating a sharp turn in reported...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agen/agenus/news/agenus-agen-q3-profit-of-us639-million-tests-longstanding-lo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agen/agenus/news/agenus-agen-q3-profit-of-us639-million-tests-longstanding-lo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620403922","title":"Agenus to present preliminary BOT+BAL first-line MSS metastatic colorectal cancer data at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403922","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403922?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:40","pubTimestamp":1773780025,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire  on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL79MDsX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620418564","title":"Agenus Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620418564","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620418564?lang=en_us&edition=fundamental","pubTime":"2026-03-17 07:38","pubTimestamp":1773704289,"startTime":"0","endTime":"0","summary":"Agenus Inc reports results for the quarter ended December 31 - Earnings SummaryAgenus Inc AGEN.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter ended December 31, higher tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N4042I0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619462226","title":"Agenus: Advancing BATTMAN Phase 3 and Leveraging Zydus Partnership to Strengthen Risk‑Reward Profile and Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2619462226","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619462226?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:25","pubTimestamp":1773674717,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agenus, retaining the price target of $23.00. Emily Bodnar has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/agenus-advancing-battman-phase-3-and-leveraging-zydus-partnership-to-strengthen-risk‑reward-profile-and-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/agenus-advancing-battman-phase-3-and-leveraging-zydus-partnership-to-strengthen-risk‑reward-profile-and-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGEN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agenusbio.com","stockEarnings":[{"period":"1week","weight":-0.0051},{"period":"1month","weight":0.1475},{"period":"3month","weight":0.2508},{"period":"6month","weight":0.021},{"period":"1year","weight":0.2389},{"period":"ytd","weight":0.2389}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.053848},{"month":2,"riseRate":0.346154,"avgChangeRate":0.006143},{"month":3,"riseRate":0.37037,"avgChangeRate":-0.033364},{"month":4,"riseRate":0.518519,"avgChangeRate":0.074851},{"month":5,"riseRate":0.5,"avgChangeRate":0.041038},{"month":6,"riseRate":0.576923,"avgChangeRate":0.079989},{"month":7,"riseRate":0.5,"avgChangeRate":-0.01535},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.024663},{"month":9,"riseRate":0.192308,"avgChangeRate":-0.071683},{"month":10,"riseRate":0.346154,"avgChangeRate":-0.078113},{"month":11,"riseRate":0.538462,"avgChangeRate":0.045072},{"month":12,"riseRate":0.192308,"avgChangeRate":-0.060665}],"exchange":"NASDAQ","name":"Agenus","nameEN":"Agenus"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agenus(AGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agenus(AGEN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agenus,AGEN,Agenus股票,Agenus股票老虎,Agenus股票老虎国际,Agenus行情,Agenus股票行情,Agenus股价,Agenus股市,Agenus股票价格,Agenus股票交易,Agenus股票购买,Agenus股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agenus(AGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agenus(AGEN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction